Condition: Liver Cancer · Esophageal Cancer · Colorectal Cancer · Sponsor: University of Colorado, Denver
The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with virulent tumor biology.
This description comes directly from the study's public registry record.
Tracey MacDermott, BA BS CCRC · 303-724-2757 · tracey.macdermott@cuanschutz.edu
Ivan Rodriguez, MD · ivan.rodriguez@cuanschutz.edu
Always discuss trial participation with your own doctor first.
| University of Colorado Denver | Aurora, Colorado, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05517811